203
Views
5
CrossRef citations to date
0
Altmetric
Case Reports

Topical carbonic anhydrase inhibitors in macular edema associated with Alström syndrome

, , , &
Pages 427-429 | Received 21 May 2015, Accepted 09 Sep 2015, Published online: 19 Feb 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Articles from other publishers (4)

Juan C Herranz-Heras, Ana Barceló, Juan F Quesada-Espinosa, Ana M Dorado-Lopez-Rosado, Pilar Tejada-Palacios & Alicia Muñoz-Gallego. (2022) Alström syndrome: Two clinical cases with two novel pathogenic variants. European Journal of Ophthalmology 33:4, pages NP27-NP31.
Crossref
Marianne Levon Shahsuvaryan. 2021. The Carbonic Anhydrases: Current and Emerging Therapeutic Targets. The Carbonic Anhydrases: Current and Emerging Therapeutic Targets 79 102 .
KaiChing Peter Leung & TakChuen Simon Ko. (2020) Childhood cone–rod dystrophy with macular cyst formation in ABCA4 mutation identified by serial spectral-domain optical coherence tomography . Taiwan Journal of Ophthalmology 0:0, pages 0.
Crossref
Elena Piozzi, Salvatore Alessi, Silvia Santambrogio, Giovanni Cillino, Marco Mazza, Aissa Iggui & Salvatore Cillino. (2017) Carbonic Anhydrase Inhibitor with Topical NSAID Therapy to Manage Cystoid Macular Edema in a Case of Gyrate Atrophy. European Journal of Ophthalmology 27:6, pages e179-e183.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.